Siemens
Siemens
Siemens
siemens
siemens
siemens
siemens

Fibralign Announces CE Mark Approval for BioBridge®

Tuesday, September 15, 2020

Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first product, the BioBridge® Collagen Matrix. BioBridge is classified as a Class III device with an indication for use to support lymphatic tissue repair and can be used after or in conjunction with surgical procedures addressing lymphedema.

CE mark is a certification symbol in Europe that signals conformity to patient safety and device performance standards applicable in the region. The certification mark confirms that BioBridge meets the requirements of the European Medical Devices Directive, which now allows Fibralign to market BioBridge across the European Union and other CE mark countries.

Fibralign also received an updated ISO 13485:2016 certification of its quality management system.  This certification demonstrates the company’s focus on quality and its ability to meet the global International Standards Organization (ISO) requirements and standards for the design, manufacture and distribution of medical devices.